ARCHITECT STAT TROPONIN-I
Report
- Report Number
- 1415939-2013-00256
- Event Type
- Malfunction
- Date Received
- June 3, 2013
- Report Date
- May 21, 2013
- Manufacturer
- ABBOTT LABORATORIES
- Product Code
- MMI
- PMA / PMN Number
- K041192
- Product Problem
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- SZ
- Reporter Occupation
- OTHER
Narratives
AN EVALUATION IS IN PROCESS. A FOLLOW-UP REPORT WILL BE SUBMITTED WHEN THE EVALUATION IS COMPLETE. (B)(4).
A STUDY WAS PERFORMED TO EVALUATE ASSAY PERFORMANCE. AN INTERNAL TROPONIN-I PANEL WAS TESTED WITH IN-HOUSE STORED ARCHITECT STAT TROPONIN-I REAGENT LOT 06017UN13 (ALL OF THE MATERIALS UTILIZED IN TESTING WERE STORED AND MAINTAINED AT OUR FACILITY). THE TROPONIN-I PANEL IS TARGETED TO A KNOWN CONCENTRATION. THE PANEL WAS WITHIN SPECIFICATION, WHICH DEMONSTRATES THAT THE ASSAY CAN ACCURATELY DETECT A KNOWN CONCENTRATION OF TROPONIN-I. A REVIEW OF COMPLAINT TRACKING AND TRENDING METRICS WAS PERFORMED AND IDENTIFIED NO ADVERSE TRENDS IN CONJUNCTION WITH THE COMPLAINT ISSUE CURRENTLY UNDER EVALUATION. THE ARCHITECT STAT TROPONIN-I ASSAY PACKAGE INSERT CONTAINS INFORMATION TO ADDRESS THE CURRENT CUSTOMER ISSUE. THE COMPLAINT TEXT INDICATED THAT IT IS UNKNOWN IF THE SAMPLES WERE HANDLED ACCORDING TO THE PACKAGE INSERT. ADDITIONALLY, REPEAT OF THE SAMPLES OR REDRAWS GENERATED NEGATIVE OR LOWER RESULTS. WITH THE INFORMATION FROM THE CUSTOMER SITE AND WITH THE RESULTS OF THE CURRENT EVALUATION, IT IS DEMONSTRATED THAT THE ARCHITECT STAT TROPONIN-I ASSAY, LOT 06017UN13, IS PERFORMING AS EXPECTED. A PRODUCT MALFUNCTION WAS NOT IDENTIFIED.
THE CUSTOMER REPORTS A FALSELY ELEVATED ARCHITECT STAT TROPONIN-I ASSAY RESULT FOR ONE FEMALE PATIENT. AN INITIAL RESULT OF 0.156 UG/L WAS GENERATED. THE CUSTOMER USES A CUT-OFF VALUE OF 0.013 UG/L FOR FEMALE PATIENTS. THE SAMPLE WAS IMMEDIATELY RETESTED AND GENERATED AN ELEVATED RESULT OF 0.094 UG/L. THE FOLLOWING MORNING, A NEW SAMPLE WAS DRAWN AND TESTED FROM THIS PATIENT AND GENERATED ARCHITECT STAT TROPONIN-I RESULTS OF 0.000 AND 0.000 UG/L. THE PATIENT'S PHYSICIAN HAD THE INITIAL SAMPLE RETESTED, WHICH GENERATED AN ELEVATED RESULT OF 0.071 UG/L. THE CUSTOMER USES ONLY ONE CONTROL TARGETED AT 7.128 UG/L AND STATED THAT THE CONTROL WAS WITHIN SPECIFICATIONS. THERE IS NO FURTHER IMPACT TO PATIENT MANAGEMENT REPORTED.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 242853 | ARCHITECT STAT TROPONIN-I | MMI | ABBOTT LABORATORIES | 06017UN13 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | SN: (B)(4).| ARCHITECT I1000SR LN: 01L86-40 |